Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemotherapy and Surgery +/- Radiotherapy in Operable Squamous Cell Carcinoma of the Oral Cavity
NCT00002747Phase 3Unknown
- Sponsor
- European Institute of Oncology
- Start
- Sep 1992
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin and fluorouracil in squamous cell carcinoma of the oral cavity (OSCC) (2 arms), sponsored by European Institute of Oncology. Primary endpoints: Short- and long-term local control rates, Disease-Free Survival and 1 more. Status: unknown.
02
Drugs
cisplatinfluorouracil
03
Conditions
squamous cell carcinoma of the oral cavity (OSCC)
Beyond the preview
Go deeper on NCT00002747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002747.